Geropsychopharmacology: Enhancing Benefit, Reducing Risk

老年精神药理学：增强效益，降低风险

• 批准号: 6463316
• 负责人: BRUCE G POLLOCK
• 金额: $ 11.76万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6463316
• 关键词: Alzheimer's disease; antidepressants; antipsychotic agents; citalopram; dementia; gene environment interaction; genetic polymorphism; geriatrics; hospital patient care; human old age (65+); human subject; human therapy evaluation; mental disorder chemotherapy; outpatient care; patient oriented research; pharmacokinetics; postdoctoral investigator; psychological tests; psychopharmacology; risperidone; serotonin inhibitor; therapy adverse effect; therapy compliance

Description (provided by applicant): Patents older than age 65 represent 13 percent of the U.S. population, yet they receive more than 35 percent of all prescription drugs and disproportionately suffer adverse experiences from psychotropic medications. The critical gaps in our knowledge of appropriate pharmacotherapy for elders with psychiatric illness are exacerbated by the shortage of new investigators trained in geriatric clinical pharmacology. This K24 award addresses this important problem by supporting further career development for an established investigator in geriatric psychopharmacology and his mentoring of junior investigators in patient-oriented research. The overarching goal of this candidate's research program is to determine inter-individual pharmacokinetic and pharmacodynamic variables affecting treatment outcome as well as to specifically address the dearth of information regarding newer antidepressants and antipsychotics in elderly patients. The primary developmental goal during the proposed K24 award period is for the candidate to enhance his expertise in population pharmacokinetics using mixed-effects modeling. This builds on the current strengths of his research program, and represents a very significant enhancement by permitting more optimal utilization of sparse drug concentration data from clinical trials. The secondary developmental goal is for the candidate to deepen his knowledge of basic and quantitative genetics. Developmental activities will occur primarily in the context of the candidate's current R01 "Continuation Pharmacotherapy for Agitation in Dementia". The goal of this study is to improve the treatment of non-cognitive symptoms of dementia in severely affected patients. This protocol will test if the highly selective serotonin reuptake inhibitor (SSRI) citalopram and the atypical antipsychotic risperidone are differentially effective in ameliorating behavioral symptoms and/or psychosis particularly during continuing pharmacotherapy upon discharge from a hospital setting. The candidate also proposes to enhance his skills as a mentor by working closely with experienced medical educators. He will recruit at least two new trainees per year through three Departmental training grants with which he is closely associated. Trainees will be medical students, residents, post-doctoral fellows and junior faculty. Particular emphasis will be given to increasing recruitment of under-represented minorities. The applicant will mentor trainees in analyses of existing data as well as design and implementation of clinical studies. Success in mentoring will be judged by trainee's productivity in peer-reviewed publications and competition for career development awards and research funding.

描述（申请人提供）：年龄超过65岁的专利代表13项 占美国人口的 %，但他们却收到了超过 35% 的人口 处方药并不成比例地遭受不良经历 精神药物。我们在适当的知识方面的关键差距 患有精神疾病的老年人的药物治疗因 缺乏接受过老年临床药理学培训的新研究者。这 K24 奖通过支持进一步的职业生涯解决了这一重要问题 老年精神药理学领域知名研究者的发展 他对初级研究人员进行以患者为导向的研究的指导。这 该候选人研究计划的总体目标是确定 影响个体间药代动力学和药效学变量 治疗结果以及具体解决信息缺乏的问题 关于老年患者的新型抗抑郁药和抗精神病药。这 拟议的 K24 奖励期内的主要发展目标是 候选人增强其在群体药代动力学方面的专业知识 混合效应建模。这是建立在他当前研究优势的基础上的 计划，并通过允许更多的 临床试验中稀疏药物浓度数据的最佳利用。这 次要发展目标是让候选人加深对以下方面的了解 基础和数量遗传学。发育活动将主要发生 在候选人当前的 R01“持续药物治疗”的背景下 痴呆症中的躁动”。这项研究的目的是改善 治疗严重受影响患者的痴呆症非认知症状。 该方案将测试高选择性血清素再摄取抑制剂是否 (SSRI) 西酞普兰和非典型抗精神病药利培酮有差异 尤其能有效改善行为症状和/或精神病 出院后继续药物治疗期间。 候选人还建议通过工作来提高他作为导师的技能 与经验丰富的医学教育者密切合作。他将招募至少两名新人 每年通过三项部门培训补助金培训学员 是密切相关的。学员将是医学生、住院医师、博士后 研究员和初级教师。 将特别强调增加 招募代表性不足的少数群体。申请人将指导学员 分析现有数据以及临床研究的设计和实施。 指导是否成功将根据受训者在同行评审中的生产力来判断 职业发展奖项和研究的出版物和竞赛 资金。